ROSEN, COUNSEL INVESTOR TRUSTED, Promoting Athenex, Inc. Investors to Secure Advisor Before important deadline May 3 – ATNX
Partner therapy announces publication of clinical trial results show significant benefit of using Leukine® (sargramostim) in patients with Alzheimer’s disease
Data Presented at ENDO 2021 Differentiate LUM-201 from General Growth Hormone Secretagogues and Additional Support LUM-201’s Potential as Therapeutic for Pediatric Growth Hormone Deficiency Nasdaq: LUMO